Matthew Offord
Main Page: Matthew Offord (Conservative - Hendon)Department Debates - View all Matthew Offord's debates with the Leader of the House
(12 years, 7 months ago)
Commons ChamberGiven the increasing number of people in this country who have been diagnosed with wet age-related macular degeneration, will a Minister come to the Dispatch Box and advise us why the National Institute for Health and Clinical Excellence refused to license the use of Avastin when it has been proved to be much cheaper than the use of Lucentis?
The Macular Disease Society is based in my constituency in Andover, and I have very close links with it. The short answer to my hon. Friend’s question is that the manufacturer of Avastin, Roche, has not applied to the relevant authority for a licence to treat wet AMD with this particular product. It is up to it to make the application. In the meantime, a licence has been granted to Lucentis, which is slightly more expensive, but I hope as effective.